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Abstract
Background Clinically relevant endpoints cannot be
routinely targeted with reasonable power in a small study.
Hence, proof-of-concept studies are often powered to a
primary surrogate endpoint. However, in acute heart failure
(AHF) effects on surrogates have not translated into clin-
ical benefit in confirmatory studies. Although observing an
effect on one of many endpoints due to chance is likely,
observing concurrent positive trends across several out-
comes by chance is usually unlikely.
Methods Pre-RELAX-AHF, which compared 4 relaxin
doses with placebo in AHF, has shown favourable trends
versus placebo (one-sided P \ 0.10) on six of nine clin-
ical endpoints in the 30 lg/kg/day group. To illustrate
evaluation of multiple, correlated clinical endpoints
for evidence of efficacy and for dose selection, a per-
mutation method was applied retrospectively. By randomly
re-assigning the treatment group to the actual data for
each of the 229 subjects, 20,000 permutation samples
were constructed.
Results The permutation P value for at least six favour-
able trends among nine endpoints in any dose groups was
0.0073 (99.9% CI 0.0053–0.0093). This is higher than
would be expected if the endpoints were uncorrelated
(0.00026), but much lower than the probability of observ-
ing one of nine comparisons significant at the traditional
two-sided P \ 0.05 (0.74). Thus, the result was unlikely
due to correlated endpoints or to chance.
Conclusions Examining consistency of effect across
multiple clinical endpoints in a proof-of-concept study may
identify efficacious therapies and enable dose selection for
confirmatory trials. The merit of the approach described
requires confirmation through prospective application in
designing future studies.
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Introduction
Cardiovascular medicine has made dramatic advances in
recent decades, partly due to effective discovery programs
that have successfully progressed through the phases of
development. Proof-of-concept studies must provide a
strong bridge between mechanistic, pharmacokinetic and
pharmacodynamic studies, and confirmatory studies for
efficacy. These studies often have designs for effects of
new interventions on a single primary outcome. Since a
small sample size (of up to 350 patients) has insufficient
power for clinically significant treatment targets (such as
dyspnea relief or cardiovascular death), many proof-of-
concept studies address surrogate endpoints so as to have
adequate power. However, positive effects on such surro-
gate endpoints (e.g., wedge pressure, BNP) may not
translate into obvious clinical benefit in later studies. For
instance, if an efficacious intervention does not affect a
surrogate this will lead to a false-negative proof-of-concept
study result and may lead to abandoning the intervention
and not pursuing the intervention in confirmatory studies.
On the other hand, ineffective interventions may have
apparent positive effects on surrogates (false-positive)
leading to unnecessary confirmatory studies in which the
true lack of efficacy is discovered after years of futile effort
[1]. Consequently, the selection of endpoints for proof-of-
concept studies has become a major challenge in acute
heart failure (AHF) research.
A possible solution to this dilemma is to design proof-of-
concept studies to explore whether a therapy demonstrates
consistent indications of a possible clinical benefit for mul-
tiple endpoints that are relevant to the disease. If an inter-
vention’s effect is examined on six endpoints—for instance,
symptoms, recurrent disease, readmission, death, quality of
life and functional improvement—having a positive effect
on one of them (for example, symptoms only) and no effect
on the other endpoints may represent a chance finding and
not a real beneficial effect. If, on the other hand, the inter-
vention improves symptoms, reduces disease recurrence and
re-admissions and improves quality of life, the probability
that all these beneficial effects are the result of chance and
not a real benefit of the intervention is low. Subsequent
studies can then confirm the therapy’s potential benefit.
We have investigated the value of this approach in the
Preliminary study of RELAXin in Acute Heart Failure
(Pre-RELAX-AHF) [2, 3]. The purposes of this study were
to assess the potential clinical efficacy of the new inter-
vention, to choose a dose from among four active doses for
further study, to assess the distributions of the endpoints,
and to re-assess the sample size needed for a subsequent
confirmatory study. Although the protocol identified pri-
mary and secondary endpoints, the analysis plan recog-
nized that the sample size did not provide adequate power
to detect statistically significant differences, and so the
overall pattern of results was to guide the dose selection for
the subsequent confirmatory study. In the main study
manuscript [3], a consistent, U-shaped dose response was
described across multiple endpoints recognized as treat-
ment targets in AHF, but given the modest sample size,
many of their P values were not statistically significant at
the traditional two-sided 0.05 level. In this paper, we
examine the usefulness of a method, called a permutation
criterion, for quantitatively evaluating the totality of the
data for evidence of efficacy and for choosing among
multiple doses.
Methods
A permutation criterion, also known as a re-randomization
criterion, is a statistical method based on the distribution of
all possible results when treatment groups are reassigned to
subjects. A permutation sample is generated by taking the
observed data for each subject, and randomly re-assigning
the treatment group to the subjects in the same ratio as in
the original sample. This procedure is then repeated mul-
tiple times to obtain many permutation samples. The sta-
tistical assessments of interest are generated for each
permutation sample. If the treatment has an effect, then one
would expect the observed pattern of results to occur rarely
among these re-randomized samples. Fisher’s exact test,
with which many researchers are familiar, is a permutation
test for a single dichotomous endpoint.
In a proof-of-concept study with multiple endpoints,
criteria can be established for evidence of efficacy and for
choosing a dose. A possible criterion for evidence of effi-
cacy can be based on P values from univariate pairwise
comparisons of each dose with placebo for all candidate
endpoints; e.g., positive ‘trends’ with one-sided P \ 0.10
(equivalent to two-sided P \ 0.20 favouring active drug)
for the majority of the endpoints is applicable, and its
occurrence by chance can have assessment across permu-
tation samples. The dose with the most positive trends
among the endpoints could be the selected dose. With this
criterion, the number of positive trends in each dose group
is calculated, and the proportion of permutation samples
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with that number or more positive trends is computed. This
proportion represents the probability of obtaining at least
the observed number of positive trends by chance alone.
Thus, no adjustment for multiple endpoints is needed, as
the single global null hypothesis that all nine endpoints for
each dose are no different or worse than placebo is being
assessed (with a single associated permutation P value)
against the alternative of a preponderance of results in
favour of at least one dose. The criterion for dose selection
may be further restricted, for example, by further requiring
nonnegative trends (one-sided P [ 0.90, equivalent to two-
sided P \ 0.20 favouring placebo).
Pre-RELAX-AHF was a parallel-group, randomized,
dose-ranging study in 234 patients with AHF [2, 3]
(ClinicalTrials.gov identifier NCT00520806). Patients with
dyspnea, pulmonary congestion, elevated BNP or NT-pro-
BNP, mild to moderate renal impairment, and systolic
blood pressure [125 mmHg were randomly assigned
within 16 h of presentation to 48 h of continuous IV
infusion of placebo, or 10, 30, 100, or 250 lg/kg/day
relaxin in a 3:2:2:2:2 ratio. The study complied with the
Declaration of Helsinki and was approved by appropriate
ethics committees. All patients gave written, informed
consent prior to study participation. Five randomized
subjects were not treated with study drug and were
excluded from the analyses. Subject self-report of dyspnea
and physician-assessed heart failure signs and symptoms
were recorded at 6, 12, and 24 h, daily through day 5, and
at day 14 following randomization. Subjects were con-
tacted at days 30 and 60 to obtain rehospitalization infor-
mation and vital status and at day 180 to ascertain vital
status. This proof-of-concept study was conducted to
determine whether a confirmatory study for IV relaxin was
warranted in this patient population, and, if so, to identify a
dose, to select endpoints, and to provide a basis for sample
size calculations. The pattern of results across nine clinical
outcomes was evaluated with one-sided P values \0.10 in
favour of active treatment considered indicative of poten-
tial efficacy. The endpoints of interest and the analytic
method used to compare groups with respect to each out-
come are given in Table 1.
For this study, 20,000 permutation samples were gen-
erated by re-randomizing the 229 treated patients (with all
their data kept intact) 20,000 times. This number of sam-
ples would allow estimation of a permutation P value of
0.01 within ±0.0023 with 99.9% confidence. Each per-
mutation sample had a 61-patient placebo group and 40-,
42-, 37-, and 49-patient groups for 10, 30, 100, 250, lg/kg/
day relaxin. For each permutation sample, comparisons of
each relaxin dose group versus placebo for each of the nine
outcomes of interest described in Table 1 were conducted,
and the number of such assessments with positive trends in
favour of that dose group was calculated. The maximum
number of positive trends among the four dose groups was
then taken for each permutation sample as the criterion for
expressing efficacy of the best dose across the nine end-
points; for example, if 0, 2, 3, and 4 positive ‘trends’ were
observed among the four dose groups, then the maximum
was 4 for that sample. The proportion of permutation
samples for which their maximum number of favourable
trends across the four dose groups is at least as large as that
actually observed for the study is the single P value for the
global null hypothesis that none of the four doses are better
than placebo for any of the nine endpoints, and such
Table 1 Statistical analysis of outcomes of interest
Variable Statistical test Effect measure
Moderately or markedly better dyspnoea at 6, 12, and
24 h as assessed by Likert scale
Wald chi-square from logistic regression model
adjusted for region
Odds ratio
Area under the curve representing the change from
baseline to Day 5 in dyspnoea as assessed by Visual
Analog Scale (VAS)
F test from analysis of variance model adjusted for
region
Mean difference
Worsening heart failure to Day 5 Wilcoxon rank sum test of days to WHF (no WHF
assigned 6 days)
Mean score
difference
Increase C25% in serum creatinine from baseline to
Day 5
Wald chi-square from logistic regression model
adjusted for region
Odds ratio
Increase C0.3 mg/dL in serum creatinine from baseline
to both Day 5 and Day 14
Wald chi-square from logistic regression model
adjusted for region
Odds ratio
Length of initial hospital stay Wilcoxon rank sum test stratified by region (in-hospital
death assigned max ? 1 days)
Mean difference
Days alive out of hospital to Day 60 Wilcoxon rank sum test stratified by region Mean difference
Cardiovascular death or rehospitalization for heart
failure or renal failure to Day 60
Wald chi-square from Cox regression Hazard ratio
Cardiovascular death to Day 180 Fisher’s exact test of incidence densities Odds ratio
Clin Res Cardiol (2011) 100:745–753 747
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assessment has adjustment for the multiplicity in its
4 9 9 = 36 underlying comparisons.
Results
The results observed in the 229 subjects enrolled in Pre-
RELAX-AHF have been described in detail [3]; one-sided
P values observed in these subjects for the outcomes of
interest are given in Table 2. Statistical assessments for six
of the nine variables comparing relaxin 30 lg/kg/day to
placebo in the study had one-sided P \ 0.10, indicating
results that favoured relaxin. The number of favourable
P values for the 10, 100, and 250 lg/kg/day groups were
lower, and the higher dose groups had outcomes with
unfavourable direction (one-sided P [ 0.90). The 30 lg/
kg/day was chosen for a confirmatory study [3]. This dose
group had the greatest number of favourable outcomes with
one-sided P \ 0.10, and had no unfavourable results with
one-sided P [ 0.90 (equivalent to a two-sided P value
\0.20).
Table 3 illustrates results for 10 of the 20,000 permu-
tation samples, each of which was constructed by randomly
reassigning the treatment group label to the 229 subjects’
actual data. For each permutation sample, the effect esti-
mate and P value for each of the 9 endpoints for each of the
4 permuted dose group comparisons against placebo—a
total of 36 comparisons—were computed. Results for 3 of
these 36 comparisons (one permuted dose group compared
against placebo for 3 of the 9 endpoints), and the number of
endpoint comparisons out of 9 with a positive trend for that
dose group, are shown for the 10 illustrative permutation
samples in Table 3.
Table 4 contains the P values computed across the 20,000
permutation samples. Computed as the proportion of per-
mutation samples where the number of positive trends was as
large or larger than the possible values 1 through 9, these
represent the probability of observing that number of posi-
tive trends or more by chance. The permutation P value for
any dose versus placebo (given in the next to last column of
Table 4) was computed as the proportion of permutation
samples where the maximum number of positive trends in
any dose group was at least as large as the respective possible
value, and represents a P value adjusted for the multiple
comparisons across the four dose groups. In Pre-RELAX-
AHF, the maximum number of positive trends (one-sided
P values \ 0.10) was six among the nine tested and was
observed in the relaxin 30 lg/kg/day group; the permutation
P value for this observed result (with multiplicity adjustment
for four doses) was 0.0073 (99.9% confidence interval
0.0053–0.0093). As one might expect, the multiplicity-
adjusted permutation P value for observing six of nine one-
sided P values \ 0.10 with the further restriction that all nine
P values B 0.90 (indicating no negative trends) in any
dose group was slightly smaller: 0.0072 (99.9% CI
0.0052–0.0092). Table 4 additionally shows permutation
Table 2 One-sided P values observed in Pre-RELAX-AHF for comparisons of each dose group with placebo
Endpoint Relaxin
10 lg/kg/day
Relaxin
30 lg/kg/day
Relaxin
100 lg/kg/day
Relaxin
250 lg/kg/day
Moderately or markedly better dyspnea at 6, 12, and 24 h by
Likert scale
0.268 0.022 0.860 0.569
Dyspnoea VAS area under the change from baseline curve from
baseline to Day 5
0.077 0.055 0.082 0.154
Time to worsening heart failure to Day 5 (no WHF assigned
6 days)
0.376 0.145 0.201 0.077
Increase C25% in serum creatinine from baseline to Day 5 0.310 0.874 0.977 0.937
Increase C0.3 mg/dL in serum creatinine from baseline to both
Day 5 and Day 14
0.565 0.550 0.765 0.907
Length of initial hospital stay (in-hospital death assigned
max ? 1 day)
0.181 0.089 0.373 0.102
Days alive out of hospital to Day 60 0.200 0.082 0.202 0.024
Cardiovascular death or rehospitalization for heart failure or renal
failure to Day 60
0.160 0.026 0.117 0.043
Cardiovascular death to Day 180 0.075 0.023 0.083 0.265
No. of one-sided P values \0.1 (trends) out of 9 supporting dose 2 6 2 3
No. of one-sided P values [0.9 (trends) out of nine against dose 0 0 1 2
One-sided P \ 0.5 favours relaxin and P [ 0.5 favours placebo
 One-sided P \ 0.10 corresponds to two-sided P \ 0.20 favouring relaxin
 One-sided P [ 0.90 corresponds to two-sided P \ 0.20 favouring placebo
748 Clin Res Cardiol (2011) 100:745–753
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P values for six or more positive trends for each dose versus
placebo without adjustment for multiplicity and they are
0.0022, 0.0021, 0.0017, and 0.0017 for the 10, 30, 100,
250 lg/kg/day doses, and their similarity supports the
comparable utility of this criterion to identify departures
from chance for the respective doses. These unadjusted
P values clearly exceed the binomial probability of 0.000064
for at least six one-sided P values B 0.10 among nine
independent assessments by chance reflecting the correla-
tions among the nine endpoints.
Discussion
Results across multiple outcomes in Pre-RELAX-AHF
suggest that relaxin may have a beneficial effect on clinical
endpoints in AHF and that the 30 lg/kg/day relaxin dose
may be promising for further study. Of the 4 doses studied,
this dose group was the only group to meet the criterion of
a majority of endpoints with one-sided P \ 0.10 favouring
relaxin compared to placebo; it had the greatest number of
favourable endpoints with one-sided P \ 0.10 (6 of 9), and
it had no unfavourable result with a one-sided
P value [ 0.90. Through a permutation criterion, we have
shown that the probability of observing such an extreme
number of favourable trends in any dose group by chance
alone is \1%. Thus, it is unlikely that the observed effect
on clinical endpoints for the 30 lg/kg/day dose is a chance
finding. We conclude that 30 lg/kg/day relaxin has
potential clinical efficacy in the treatment of AHF, and so
its effects on dyspnea relief and 60-day mortality and
morbidity—endpoints found to be responsive to therapy in
this proof-of-concept study—are being assessed in an
ongoing RELAX-AHF-1 confirmatory study.
Table 3 Example of results for 10 permutation samples for comparison of the 30 lg/kg/day relaxin dose group versus placebo for 3 of the 9
outcomes of interest
Sample # (?) trends out of 9* Mod/marked better dyspnea at 6, 12, and 24 h VAS AUC to Day 5 Persistent renal impairment
Effect P value Effect P value Effect P value
1 0 0.972 0.523 -785.614 0.928 1.853 0.807
2 0 0.768 0.717 -421.809 0.784 1.385 0.649
3 2 2.586 0.034 1096.705 0.019 0.957 0.472
4 1 1.238 0.339 -249.908 0.680 0.272 0.123
5 0 1.135 0.394 -213.555 0.654 1.633 0.744
6 2 0.995 0.504 -907.511 0.957 0.873 0.429
7 1 1.224 0.347 721.538 0.087 1.591 0.754
8 1 1.257 0.312 799.000 0.068 1.048 0.524
9 2 1.886 0.089 -374.060 0.758 0.920 0.450
10 1 1.856 0.091 101.700 0.425 0.973 0.484
* Positive (?) trend defined as one-sided P \ 0.10
 One-sided P \ 0.5 favours relaxin and P [ 0.5 favours placebo. One-sided P \ 0.10 corresponds to two-sided P \ 0.20 favouring relaxin,
while one-sided P [ 0.90 corresponds to two-sided P \ 0.20 favouring placebo
Table 4 Probability estimated from 20,000 permutation samples of given number of positive trends or more out of 9 outcomes of interest
Number of one-sided P \ 0.1
(in favour of active treatment)
P value for comparison of permuted dose group Relaxin dose group(s)
in which result observed
(lg/kg/day)10 lg v.
placebo
30 lg v.
placebo
100 lg v.
placebo
250 lg v.
placebo
Any dose group v.
placebo
1 0.5080 0.5056 0.4983 0.5053 0.8810
2 0.2120 0.2130 0.2062 0.2179 0.5240 10 , 100
3 0.0758 0.0783 0.0727 0.0838 0.2333 250
4 0.0249 0.0289 0.0249 0.0310 0.0911
5 0.0075 0.0081 0.0072 0.0089 0.0288
6 0.0022 0.0021 0.0017 0.0017 0.0073 30
7 0.0004 0.0006 0.0003 0.0004 0.0019
8 0 0.0001 0 0 0.0003
9 0 0 0 0 0.0000
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Dose selection and proof of activity are often based on a
surrogate endpoint (such as a biomarker) for which a study
with small sample sizes can have insufficient power.
However, such a surrogate endpoint may not be predictive
of the drug’s effect on clinical outcomes in a confirmatory
study. Reliance on a single, primary, surrogate outcome
measure in proof-of-concept studies may lead to decisions
that would not be confirmed, including false-positive
results driven by an effect of the intervention on the sur-
rogate but no activity on the disease, false-negatives and
the abandoned development of potentially beneficial ther-
apies, or in the selection of an inappropriate dose for fur-
ther study. A novel approach that has been recently
incorporated into the design of cardiovascular clinical trials
is to examine multiple clinical outcomes for evidence of a
drug’s activity and worthiness for further evaluation.
Several studies have evaluated multiple clinical end-
points, but the approach taken in integrating results across
these multiple endpoints has varied. One approach is to
assign a score to each subject by assigning values based on
results over the endpoints. For example, in the African-
American Heart Failure Trial (AHeFT), subjects were
assigned a rank score from -6 to ?2 based on weighted
values for all-cause mortality, first heart failure rehospi-
talization, and quality of life score [4]. This ranked com-
posite outcome was then used as the primary outcome for
comparing treatment groups. A similar criterion has been
proposed for use in trials of mechanical circulatory support
devices [5], and in AHF studies [6]. In the end, the risks of
the therapy must be weighed against the potential benefit,
and an advantage of the ranked individual outcome is that
the risks and benefits to the individual patient are incor-
porated in the criterion. The disadvantage of such an
approach, however, is in the difficulty interpreting the
criterion: several different outcome combinations could
result in the same score, and a therapy might affect some
components in one direction and others in a different
direction. Simpler, three-category ordered outcomes (suc-
cess, unchanged, failure) have been used in several AHF
programs, including the REVIVE studies evaluating levo-
simendan [7] and the PROTECT studies [8, 9] evaluating
rolofylline. In designing such criteria, individual compo-
nents must be chosen and weighted such that a favourable
score reflects benefit outweighing risk to a meaningful
degree.
Another potentially useful approach in exploratory
studies where the most sensitive endpoint to the therapy is
unknown is to analyse multiple endpoints individually and
look for consistency of results across the endpoints. For
example, in the design of the CUPID study, researchers
considered as evidence of efficacy ‘‘improvement’’ (two-
sided P \ 0.2 for an endpoint with favourable point esti-
mates for other endpoint(s) within the domain) in 2 of 5
efficacy ‘domains’ on a study-level, or two-sided P \ 0.2
on a subject-level composite outcome of success/unchan-
ged/failure based on improvement in at least one efficacy
endpoint without worsening on any others [10]. They
estimate the probability of a ‘false-positive’ given this
approach to be\0.10 assuming a lack of correlation among
the domains.
Other approaches involve computation of a global sta-
tistic across multiple endpoints. A multivariate test such as
Hotelling’s T2 allows comparison of groups regarding
multiple endpoints simultaneously, but can be insensitive
to situations in which individual endpoints are not statis-
tically significant, but the pattern of results suggests effi-
cacy [11]. O’Brien [11] suggested a global rank-sum-type
test, based on a simple or weighted sum of ranks across the
individual endpoints. This method is powerful only if the
treatment effects on all endpoints are in the same direction.
This limitation could be handled with a step-down
approach to testing each individual endpoint given rejec-
tion of a global null hypothesis of no effect [12], or through
weighting of the individual endpoints in an attempt to
create an overall benefit-to-risk measure.
The permutation criterion described here allows an
assessment of multiple endpoints simultaneously with
consideration of the direction of the treatment effect. The
method is flexible, and can be adapted to examine different
hypotheses. In Pre-RELAX-AHF, we have computed a
multiplicity adjusted P value based on the number of
endpoints with favourable trends, given the observed data
including the correlation structure, allowing an informed
decision regarding the role of chance in the findings.
Results of the RELAX-AHF-1 study will either confirm or
refute the efficacy of the selected relaxin dose on primary
and secondary endpoints chosen from among those in the
proof-of-concept study.
A common misconception is that evaluating several
clinical outcomes simultaneously increases the probability
of a false signal [13]. Although it is true that the probability
of obtaining at least one ‘‘positive’’ result from a long list
of potential variables is higher than the nominal P value
used for each of the multiple outcomes, requiring demon-
stration of multiple concurrent effects does not necessarily
increase the likelihood of a chance finding. Assuming
independence (or no correlation) among the clinical out-
comes of interest, the probability of observing the pairwise
comparison of a dose and placebo for one of nine endpoints
significant at the traditional, one-sided 0.025 level by
chance alone would be 0.184, while the chance of
observing at least six of nine positive trends (with one-
sided P B 0.10) versus placebo in would be 0.000064. As
the correlation between the endpoints increases, the chance
of observing multiple concomitant trends becomes higher.
If the nine variables were very highly correlated (e.g., all
750 Clin Res Cardiol (2011) 100:745–753
123
correlations C0.9), the chance of observing six of nine
positive trends (one-sided P \ 0.10) would approach 0.15
[14], while if they were perfectly correlated (all correla-
tions = 1.0) the probability would be 0.10. The value
calculated for the present study (0.0017) is higher than one
would expect if all the endpoints were independent
reflecting a modest correlation among the variables.
Therefore, observing six of nine positive trends in Pre-
RELAX-AHF is not likely to be the result of either a
chance finding or that these were basically six expressions
of identical phenomena highly correlated with each other.
We have applied this approach to the Pre-RELAX-AHF
database retrospectively. Although the endpoints examined
are recognized as important endpoints in AHF studies [15,
16], the nine endpoints selected and the analytic method for
examining them concurrently were not identified prospec-
tively; thus, the proposed approach should be considered
untried. The approach could be applied prospectively when
designing future studies by identifying the endpoints to be
examined and the criteria for evidence of efficacy and dose
selection a priori. The acceptable false-positive rate should
be chosen, and then power calculations conducted to
determine the number of subjects needed. Once the study is
completed, results observed in the study population should
be compared against the criteria chosen for evidence
of effect and dose selection, and permutation P values
computed for the observed results. Each of these design
elements is considered in further detail below.
Choice of endpoints
When designing these studies, endpoints should be inclu-
ded that would be appropriate for a confirmatory study.
While surrogate endpoints might be included in addition to
clinical endpoints as evidence of effect in a proof-of-con-
cept study, these endpoints would probably not be selected
as primary endpoints in a confirmatory study. One should
also consider that the more endpoints examined, the lower
the probability of observing a majority of favourable trends
by chance alone. For example, if the endpoints selected
were uncorrelated, the probability of at least four of seven
positive trends by chance alone is 0.0027, while for at least
five of nine, it is 0.00089. As described above, correlation
among the endpoints reduces the ability to determine
effects by observing multiple trends and is analogous to
reducing the number of endpoints, thus increasing the
probability of observing multiple positive trends by chance
alone. Therefore, endpoints should be selected that are not
too highly correlated with one another. However, this may
introduce a dilemma since it may not be known a priori
which endpoint within a ‘domain’ might be most sensitive
to the treatment. One example is dyspnoea relief which
could be measured using either a Likert scale where the
patient compares their symptoms to baseline or a visual
analogue scale where the patient rates their symptoms at
each point in time and effects could be measured either at 6
and 24 h or over 5 days. A possible solution is to compute
an overall P value within each domain, and then proceed
with the evaluation of potential efficacy across domains as
described here for individual endpoints.
Once the proof-of-concept study is complete, the choice
of endpoints as primary in the confirmatory study must be
guided by both statistical and other concerns. Endpoints
with favourable results in the proof-of-concept study would
seem to have a higher probability of demonstrating a
treatment effect than untested ones or ones without evi-
dence of effect. Choosing the endpoints with the lowest
P values must be balanced, however, with study objectives.
For the RELAX-AHF-1 study, two primary endpoints were
chosen from among those tested in the proof-of-concept
study: moderately or markedly better dyspnea reported on
the Likert scale at 6, 12, and 24 h; and the area under the
change in dyspnea visual analogue scale score from base-
line to day 5. Although these were not the two endpoints
with the lowest P values in Pre-RELAX-AHF, the confir-
matory study is designed primarily to evaluate relaxin’s
effect on dyspnea relief, and a positive finding for either of
these endpoints would likely support regulatory approval
for this indication.
Choice of criteria for evidence of efficacy and dose
selection
A criterion for acceptance of proof of concept illustrated
here was a simple majority of endpoints favouring the test
treatment and with a positive trend at the one-sided 0.10
level. A criterion for evidence of effect based on a majority
of endpoints has been accepted in other research fields. For
example, the ACR20 composite endpoint in rheumatoid
arthritis defines a responder as a patient who has at least
five of seven endpoints with at least 20% improvement,
although this criterion is applied to individual patients
within a group rather to comparisons between two groups
[17]. The P value for a comparison between two groups
represents a standardized effect size that accounts for
sample size. For a continuous endpoint with equal sample
sizes in the two groups, one-sided P B 0.10 corresponds to
ffiffiffiffiffiffiffi
n=2
p
d  1:282, where d is the standardized effect size
(i.e., the ratio of the difference between the groups’ means
versus the standard deviation). With 50 subjects per group,
one-sided P B 0.10 corresponds to d C 0.256—a small
effect size with potential clinical relevance [18].
Other criteria for evidence of efficacy could be con-
structed, for example, by accepting ‘positive trends’ on
surrogate markers but requiring that clinical end-
point(s) demonstrate positive trends as well. The choice of
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criterion should be driven by consideration of an accept-
able false-positive rate which could be estimated through
simulations taking into account the correlations among the
chosen endpoints and assuming no treatment effect. After
the study is completed, the permutation P value can be
calculated using the observed results with actual correla-
tion structure.
The dose selection criterion for the confirmatory study
suggested here was to choose the dose with the most
favourable trends. It might be possible in a proof-of-con-
cept study for more than one dose group to satisfy the
criterion demonstrating potential efficacy. If one dose
group was not clearly superior to the other, both doses
could be explored further in the confirmatory study.
Power and sample size considerations
How many subjects to include in proof-of-concept studies
is an important consideration. With the approach described
here, the power obtained to detect a majority of endpoints
with positive trends is greater than that required for each
individual endpoint. If the endpoints were independent,
65% power for each of nine endpoints would provide
approximately 83% power to detect five of nine favourable
trends. Of course, higher correlations among the endpoints
may result in less power than that calculated assuming
independence. To estimate power correctly for such stud-
ies, one should assume somewhat higher correlations than
expected and strive to include more rather than fewer
patients. Power calculations can be achieved through
simulations which preferably should be based on real data
from previous programs rather than theoretical assump-
tions. This underlines the importance of sharing data freely
among different stake holders in research.
Limitations
Balancing apparent efficacy and potential safety concerns
may not be possible through purely statistical methods. The
method described in this paper is a novel approach to
assessing potential activity of new therapies, but shares the
limitation with other statistical approaches that safety
concerns may in some cases be related to single or very few
extreme events that do not approach statistical significance.
Hence, final decisions on whether a new therapy should be
further explored must involve clinical judgment balancing
efficacy and safety.
Conclusions
Examination of consistency of findings across multiple
clinical endpoints in a proof-of-concept study may be
useful in identifying efficacious therapies, and in selecting
a dose from among several tested. The permutation method
described allows a determination of the role of chance in
these findings. In this retrospective analysis, application of
this method to the Pre-RELAX-AHF proof-of-concept
study shows that the multiplicity adjusted P value for
observing at least 6 of the 9 AHF endpoints examined with
a one-sided P value \ 0.10 favouring active treatment in
one of 4 dose groups by chance alone was\1%. These data
and analyses have been used to design the ongoing
RELAX-AHF-1 confirmatory study, which will assess the
efficacy of the selected relaxin dose primarily in relieving
dyspnoea and secondarily in reducing morbidity and mor-
tality in AHF patients. The merit of the approach described
requires confirmation through prospective application in
designing future proof-of-concept studies.
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